Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEKTURNA vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Direct renin inhibitor that binds to renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and decreasing vasoconstriction and aldosterone secretion.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension (to lower blood pressure, alone or in combination with other antihypertensives)
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
150 mg orally once daily, starting dose; may increase to 300 mg once daily after 2-4 weeks if blood pressure not controlled, with or without food.
250 mg orally twice daily
Terminal elimination half-life is approximately 24 hours (range 20–40 hours), supporting once-daily dosing.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Primarily hepatic via CYP3A4; minor metabolism via other pathways. Excreted in feces (78%) and urine (22%).
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Primarily renal (88% as unchanged drug and metabolites, 33% as unchanged aliskiren); biliary/fecal elimination accounts for approximately 12%.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Approximately 50% bound to plasma proteins (primarily albumin).
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution is approximately 1.7 L/kg, indicating extensive distribution into tissues.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral bioavailability is approximately 2.5% (low due to limited absorption and high first-pass metabolism); absorption is reduced by high-fat meal (by up to 50%).
70-90% (oral); 100% (IV).
Contraindicated in GFR <30 m L/min/1.73 m². For GFR ≥30 m L/min/1.73 m², no dose adjustment required.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Not studied in severe hepatic impairment (Child-Pugh Class C).
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not approved for use in pediatric patients under 18 years of age due to lack of safety and efficacy data.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
No dose adjustment required in elderly patients; initiate therapy at 150 mg once daily and monitor renal function and blood pressure closely due to increased risk of hypotension and renal impairment.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Fetal toxicity (avoid in pregnant women; discontinue if pregnancy detected),Hypotension in volume-depleted patients,Renal impairment (monitor renal function; risk of acute renal failure in patients with bilateral renal artery stenosis),Hyperkalemia (especially in patients with renal impairment, diabetes, or on potassium-sparing diuretics),Angioedema (discontinue immediately and manage appropriately)
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Pregnancy,History of angioedema with previous renin-angiotensin system inhibitors,Concomitant use with aliskiren in patients with diabetes (age- and renal-specific restrictions)
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
High-fat meals reduce aliskiren absorption; avoid consistent consumption with high-fat foods. Grapefruit juice may decrease aliskiren levels; avoid concurrent intake. No other significant food interactions.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal injury and death when used during the second and third trimesters. Risks include oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. First trimester exposure may also carry increased risk but is less well-defined.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
No data on presence in human milk; manufacturer advises against breastfeeding due to potential adverse effects in nursing infants, including hypotension and renal impairment.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No specific dose adjustments recommended; avoid use in pregnancy, especially during second and third trimesters, due to risk of fetal harm. If pregnancy occurs, discontinue promptly.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
TEKTURNA (aliskiren) is a direct renin inhibitor used for hypertension. Monitor renal function and potassium levels due to risk of hyperkalemia and renal impairment, especially in patients with diabetes, renal artery stenosis, or concomitant ACE/ARB use. Avoid use during pregnancy (category D). Contraindicated with cyclosporine and itraconazole due to increased aliskiren exposure.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take TEKTURNA once daily with or without food, but consistently either with a meal or without.,Avoid high-fat meals as they can reduce absorption.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not use salt substitutes containing potassium without consulting your doctor.,Report symptoms like muscle cramps, irregular heartbeat, or weakness (signs of hyperkalemia).,Stay hydrated and avoid dehydration (vomiting, diarrhea, excessive sweating) as it may increase side effects.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEKTURNA vs ALDOCLOR-250, answered by our medical review team.
TEKTURNA is a Antihypertensive that works by Direct renin inhibitor that binds to renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and decreasing vasoconstriction and aldosterone secretion.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEKTURNA and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEKTURNA is: 150 mg orally once daily, starting dose; may increase to 300 mg once daily after 2-4 weeks if blood pressure not controlled, with or without food.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEKTURNA and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEKTURNA is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal injury and death when used during the second and third trimesters. Risks include oligohydramnios, fetal . ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.